Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using an UACR Endpoint study (CONFIDENCE)
Nephrol Dial Transplant 2022 Jun 14;gfac198. Online ahead of print. doi: 10.1093/ndt/gfac198.
CONFIDENCE will evaluate the safety, tolerability and efficacy of dual use of finerenone and an SGLT2i in adults with CKD and T2D. Approximately 800 patients will be randomised to finerenone plus empagliflozin, or either agent alone – with randomisation stratified by estimated glomerular filtration rate (eGFR) and urinary albumin-to-creatinine ratio (UACR) values at screening.
Should an additive effect be shown, early and efficient intervention with dual finerenone and SGLT2i could slow disease progression and provide long-term benefits for people with CKD and T2D. The trial is expected to finalise recruitment in May 2023.